Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd688505
▲ PositiveCapitalrelevance
Net profit surged 545.57% year on year due to lower R&D expenses.

Fudan-Zhangjiang released its semi-annual report for 2026, showing net profit attributable to shareholders of the listed company of 36.895 million yuan, a year-on-year increase of 545.57%. The company achieved operating revenue of 372 million yuan, down 4.58% year on year. The profit growth was mainly due to research and development expenses falling by approximately 44 million yuan compared with the same period last year.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LtdNet profit surged 545.57% year on year due to lower R&D expenses.